AI Article Synopsis
- Melanoma is prone to metastasizing to the brain, but the molecular changes that facilitate this process are not well understood.
- Identifying specific genomic and epigenomic alterations in brain metastases is crucial for understanding their aggressiveness and discovering new drug targets.
- A multi-platform dataset analyzed in a study includes DNA methylation, gene expression, SNPs, and CNV across different stages of melanoma progression, providing insights into these molecular changes.
Article Abstract
Melanoma has a high tendency to metastasize to brain tissue. The understanding about the molecular alterations of early-stage melanoma progression to brain metastasis (MBM) is very limited. Identifying MBM-specific genomic and epigenomic alterations is a key initial step in understanding its aggressive nature and identifying specific novel druggable targets. Here we describe a multi-platform dataset generated with different stages of melanoma progression to MBM. This data includes genome-wide DNA methylation (Illumina HM450K BeadChip), gene expression (Affymetrix HuEx 1.0 ST array), single nucleotide polymorphisms (SNPs) and copy number variation (CNV; Affymetrix SNP 6.0 array) analyses of melanocyte cells (MNCs), primary melanoma tumors (PRMs), lymph node metastases (LNMs) and MBMs. The analysis of this data has been reported in our recently published study (Marzese et al., 2014).
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4311262 | PMC |
| http://dx.doi.org/10.1016/j.gdata.2014.06.007 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!